Neuroleptic drugs induce psychological side effects such as dysphoria, cognitive impairment, and loss of motivation. These side effects were largely underrecognized and trivialized in the past as variants of extrapyramidal side effects (EPSEs). We review the recent literature on the subject and clarify the relation between neuroleptic-induced dysphoria and EPSEs.
Methods:
We critically examined clinical, interventional, neuroimaging, and basic science studies published in the past 10 years, delineating the temporal, phenomenological, biochemical, and neuroanatomical relation between dysphoria and EPSEs.
Results:
Subjective responses occur within 4 to 6 hours of neuroleptic use, whereas acute dystonia is often observed within 24 hours and parkinsonian syndrome after 5 to 7 days. Neuroleptic-induced dopaminergic blockade mediates both dysphoria and EPSEs. However, impaired dopamine function in the nucleus accumbens seems to give rise to dysphoria, whereas blockade of D2 receptors in the nigrostriatal system is responsible for EPSEs.
Conclusion:
The earlier notion that neuroleptic dysphoria is a variant of EPSEs was simplistic and speculative. Exploring the differences rather than dwelling on the similarities will likely enhance our understanding of dopamine's role in the origin of varied side effects and in their distinctive characteristics.
HollisterLE. Complications from the use of tranquilizing drugs. N Engl J Med1957;257:170–7.
2.
BarnesTREBraudeWM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry1985;42:874–8.
3.
Di MascioAShaderRL. Behavioural toxicity. In: Di MascioAShaderRL, editors. Psychotropic drug side effects: Clinical and theoretical perspectives. Philadelphia (PA): Williams and Wilkins; 1972. p 116–23.
4.
SerafetinidesEAClarkML. Psychological effects of a single dose antipsychotic medication. Biol Psychiatry1973;7:263–7.
5.
AwadAG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull1993;19:609–18.
6.
AwadAGHoganTP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry1985;9:585–8.
7.
AwadAGHoganTPVorugantiLNPHeslegraveRJ. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life. Int Clin Psychopharmacol1995;10(suppl 3):123–33.
8.
SachdevP.Neuroleptic dysphoria In: Akathisia and restlessness. London: Cambridge University Press; 1995. p 42–7.
9.
Van PuttenTMutalpassiLRMalkinMD. Phenothiazine-induced decompensation. Arch Gen Psychiatry1974;30:102–5.
10.
DiamondR.Drugs and quality of life: The patient's point of view. J Clin Psychiatry1985;46:29–35.
11.
D'MelloDABoltzMKMsibiB.The relationship between concurrent substance abuse in psychiatric patients and neuroleptic dose. Am J Drug Alcohol Abuse1995;21:257–65.
12.
BlylerCRFentonWS. Satisfaction with treatment outcome and non-compliance in schizophrenia. Schizophr Res1997;24:205.
13.
VorugantiLHeslegraveRJAwadAG. Neuroleptic dysphoria may be the missing link between substance abuse and schizophrenia. J Nerv Ment Disord1997;185:463–5.
14.
BuckleyP.Substance abuse in schizophrenia: A review. J Clin Psychiatry1998;59(suppl 3):6–30.
15.
AwadAG. Behavioural and subjective side effects. In: KaneJM, editor. Managing the side effects of drug therapy in schizophrenia. London: Science Press; 1999. p 1–14.
16.
LaruelleMD'SouzaCDBaldwinRMAbi-DarghamA.Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology1997;17:162–74.
17.
VorugantiLSlomkaPZabelPCostaGSoAMattarA, and others. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: The correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology2001;25:642–50.
18.
HaertzenCA. Addiction Research Centre Inventory (ARCI) development of a general drug estimation scale. J Nerv Ment Disord1965;141:300–7.
19.
HoganTPAwadAGEastwoodRC. A self-report scale predictive of drug compliance in schizophrenia: Reliability and discriminate ability. Psychol Med1983;13:177–83.
20.
AwadAGVorugantiLNPHeslgraveRJ. Assessment of the patient's subjective experiences in acute neuroleptic treatment implications for compliance and outcome. Int Clin Pyschopharmacol1996;11(suppl 2):55–60.
21.
McNairDMLorrMDropplemanL.Manual for the Profile of Mood States. San Diego (CA): Educational and Industrial Testing Services; 1992.
22.
VerhoeffNPChristensenBKHusseyDLeeMPapatheodorouGKapurS.Effects of catecholamine depletion on D2 receptors binding motivation and attentiveness in humans: A replication study. Pharmacol Biochem Behav2003;74:425–32.
23.
VorugantiLNPCorteseLOuyewumiLKottedaVZirulSAwadAG. Comparative evaluation of conventional and new antipsychotic drugs: A follow-up study. Schizophr Res2000;43:135–45.
24.
VorugantiLCorteseLOuyewumiLCernovskyJZirulSAwadAG. Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study. Schizophr Res2002;57:201–8.
AwadAGVorugantiLNP. New antipsychotics, compliance, quality of life and subjective tolerability: Are patients better off?Can J Psychiatry2004;49:297–302.
27.
FardeLHallHEhrinESedvallG.Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science1986; 231:258–61.
28.
KapurSZipurskyRBJonesCRemingtonGHouleS.Relationship between dopamine D2 occupancy, clinical response, and side-effects: A double-blind PET study of first episode schizophrenia. Am J Psychiatry2000;157:514–20.
29.
SeemanPTallericoT.Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors yet occupy high levels of these receptors. Mol Psychiatry1998;3:123–34.
30.
KapurSSeemanP.Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry2001;158:360–9.
31.
EkelundJLichtermanDJarvelinMRPeltonenL.Association between novelty seeking and the type 4 dopamine receptor gene in 9 large Finnish cohort samples. Am J Psychiatry1999;156:1435–55.
32.
KurokiTMetzerHYIchikawaJ.Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Therap1999;288:774–81.
33.
TaberMTDasSFibigerHC. Cortical regulation of sub cortical dopamine release: Medication via the ventral tegmental area. J Neurochem1995;65:1407–10.
34.
KapurSZipurskyRBRemingtonG.Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry1999;156:286–93.
35.
de HaanLLavalayeJVan BruggenMVan NimwegenLBooijJ.Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: Clinical implications. Can J Psychiatry2004;49:290–6.
36.
FujitaMVerhoeffVarroneAZoghbiSBaldwinRMJatlowPA, and others. Imaging extrastraital dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol2000;387:179–88.
37.
HietalaJSyvalahsiEVilkmanHVuorioKRäkkoläinenVBergmanJ, and others. Depressive symptoms and presynaptic dopamine functions in neuroleptic naïve schizophrenia. Schizophr Res1999;35:41–50.
38.
de HaanLLavalayeJLinszenDDingemansPMAJBooijJ.Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry2000;157:1019–20.
39.
HeimerLAlheidGde OlmosJSGroenewegenHJHaberSNHarlanR, and others. The accumbens: Beyond the core shell dichotomy. In: SallawaySPMalloyPFCummingsJL, editors. The neuropsychiatry of limbic and subcortical disorders. Washington (DC): American Psychiatric Press; 1997.
40.
VorugantiLPAwadAG. Neuroleptic dysphoria: Toward a new synthesis. Psychopharmacology2004;171:121–31.
41.
The Oxford English Dictionary. 2nd ed.Oxford (UK): Clarendon Press; 1989.
